Jacobson Center for Clinical & Translational Research

Main Menu


Additional Information


Contact Us

Epilepsy Research Studies

Study Title:  A Randomized, Double-Blind, Placebo-Controlled, Phase 2 study Exploring the Efficacy, Safety, and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects with Drug-Resistant Focal Epilepsy.   (Identifier:  NCT03283371)

Study Purpose:  The primary efficacy objective of the study is to determine if adjunctive therapy of natalizumab 300 mg intravenous (IV) every 4 weeks reduces the frequency of seizures in adult participants with drug-resistant focal epilepsy. The secondary efficacy objective is to assess the effects of natalizumab versus placebo in drug-resistant focal epilepsy on additional measures of seizure frequency.

Principal Investigator:  Imran Ali, M.D.

Study Coordinator:  For more information email Andrea Korsnack, RN, or call 419.383.3801.


Last Updated: 4/12/19